Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-9193

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease ; volume:11 ; number:1 ; day:21 ; month:3 ; year:2019 ; pages:1-12 ; date:12.2019
Alzheimer's research & therapy ; 11, Heft 1 (21.3.2019), 1-12, 12.2019

Creator: Startin, Carla M.
Ashton, Nicholas J.
Hamburg, Sarah
Hithersay, Rosalyn
Wiseman, Frances K.
Mok, Kin Y.
Hardy, John
Lleó, Alberto
Lovestone, Simon
Parnetti, Lucilla
Zetterberg, Henrik
Hye, Abdul
Strydom, André

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13195-019-0477-0

URN: urn:nbn:de:101:1-2019050219295311117126

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Startin, Carla M.
Ashton, Nicholas J.
Hamburg, Sarah
Hithersay, Rosalyn
Wiseman, Frances K.
Mok, Kin Y.
Hardy, John
Lleó, Alberto
Lovestone, Simon
Parnetti, Lucilla
Zetterberg, Henrik
Hye, Abdul
Strydom, André
SpringerLink (Online service)

Other Objects (12)

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease

Melatonin: A potential nighttime guardian against Alzheimer’s

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease

Melatonin: A potential nighttime guardian against Alzheimer’s

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease

Melatonin: A potential nighttime guardian against Alzheimer’s

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease

Melatonin: A potential nighttime guardian against Alzheimer’s

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease

Melatonin: A potential nighttime guardian against Alzheimer’s

Blood-based molecular biomarkers for Alzheimer’s disease

Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease

Melatonin: A potential nighttime guardian against Alzheimer’s

Related objects

Reset password